Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.
News|Articles|November 3, 2026
CVS Health is splitting in two, according to news reports
Author(s)Peter Wehrwein, Managing Editor
The retail pharmacies will be in one company and Aetna and CVS Caremark, the PBM, in another, according to news reports.
Advertisement
Healthcare giant CVS Health is separating itself into two separate companies, the Wall Street Journal and Financial Times are reporting.
The split, which is scheduled to happen in 2028, will result in two companies, one with the 9,000 retail pharmacies and the mail-order pharmacy business and the other with Aetna, the insurance business, and the pharmacy benefit manager (PBM), CVS Caremark, plus Signify Health, the home healthcare business, and the specialty pharmacy, according to the Journal.
The Financial Times broke the news about the restructuring. The newspaper qualified its scoop with the caution that the “structure and timeline of the break-up were still in flux and could yet change.”
News of the CVS Health dividing itself comes as lawmakers are beginning to focus on vertical integration in healthcare and the influence of companies such as CVS Health and UnitedHealth Group. Arkansas and Tennessee have passed laws that would prohibit PBMs from owning pharmacies.
This is a developing story.
Advertisement
Related to this article
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Bronchiectasis 101: Why permanently dilated airways drive recurrent exacerbations
2
CVS Health is splitting in two, according to news reports
3
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
4
From MFP fallout to AI guardrails: What stood out at AMCP Nexus 2026
5